CervoMed Statistics

Total Valuation

CervoMed has a market cap or net worth of $94.29 million. The enterprise value is $55.67 million.

Market Cap	94.29M
Enterprise Value	55.67M

Important Dates

The last earnings date was Friday, August 8, 2025, before market open.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

CervoMed has 9.25 million shares outstanding. The number of shares has increased by 43.26% in one year.

Current Share Class	9.25M
Shares Outstanding	9.25M
Shares Change (YoY)	+43.26%
Shares Change (QoQ)	+2.85%
Owned by Insiders (%)	31.44%
Owned by Institutions (%)	11.00%
Float	5.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.87
Forward PS	n/a
PB Ratio	2.67
P/TBV Ratio	2.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	7.16
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.20

Current Ratio	8.20
Quick Ratio	7.73
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -54.21% and return on invested capital (ROIC) is -36.80%.

Return on Equity (ROE)	-54.21%
Return on Assets (ROA)	-33.63%
Return on Invested Capital (ROIC)	-36.80%
Return on Capital Employed (ROCE)	-73.43%
Revenue Per Employee	$518,465
Profits Per Employee	-$1.51M
Employee Count	15
Asset Turnover	0.17
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.07% in the last 52 weeks. The beta is -6.25, so CervoMed's price volatility has been lower than the market average.

Beta (5Y)	-6.25
52-Week Price Change	-32.07%
50-Day Moving Average	7.74
200-Day Moving Average	6.98
Relative Strength Index (RSI)	66.00
Average Volume (20 Days)	817,426

Short Selling Information

The latest short interest is 728,696, so 7.88% of the outstanding shares have been sold short.

Short Interest	728,696
Short Previous Month	109,915
Short % of Shares Out	7.88%
Short % of Float	13.30%
Short Ratio (days to cover)	1.01

Income Statement

In the last 12 months, CervoMed had revenue of $7.78 million and -$22.61 million in losses. Loss per share was -$2.58.

Revenue	7.78M
Gross Profit	-14.38M
Operating Income	-24.56M
Pretax Income	-5.04M
Net Income	-22.61M
EBITDA	n/a
EBIT	-24.56M
Loss Per Share	-$2.58

Full Income Statement

Balance Sheet

The company has $33.53 million in cash and n/a in debt, giving a net cash position of $33.53 million or $3.62 per share.

Cash & Cash Equivalents	33.53M
Total Debt	n/a
Net Cash	33.53M
Net Cash Per Share	$3.62
Equity (Book Value)	33.44M
Book Value Per Share	3.61
Working Capital	33.44M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-23.31M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is -184.92%, with operating and profit margins of -315.76% and -290.75%.

Gross Margin	-184.92%
Operating Margin	-315.76%
Pretax Margin	-290.75%
Profit Margin	-290.75%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CervoMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-43.26%
Shareholder Yield	-43.26%
Earnings Yield	-25.35%
FCF Yield	n/a

Analyst Forecast

The average price target for CervoMed is $17.60, which is 72.72% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$17.60
Price Target Difference	72.72%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	13.41%
EPS Growth Forecast (5Y)	-15.25%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CervoMed has an Altman Z-Score of 6.39.

Altman Z-Score	6.39
Piotroski F-Score	n/a